| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.IJROBP.2009.05.031 |
| P698 | PubMed publication ID | 19836157 |
| P50 | author | Andreas von Deimling | Q40381084 |
| Richard Meyermann | Q66360796 | ||
| Oliver Bähr | Q97535262 | ||
| Ulrich Herrlinger | Q114726897 | ||
| Dorothee Wiewrodt | Q114726954 | ||
| Thierry Gorlia | Q116792796 | ||
| Marcos Soares Tatagiba | Q782253 | ||
| Wolfgang Wick | Q2591750 | ||
| Michael Weller | Q2779469 | ||
| P2093 | author name string | Michael Bamberg | |
| Christian Hartmann | |||
| Markus Weiler | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | glioblastoma | Q282142 |
| temozolomide | Q425088 | ||
| chemoradiotherapy | Q5090613 | ||
| P304 | page(s) | 670-676 | |
| P577 | publication date | 2009-10-14 | |
| P1433 | published in | International Journal of Radiation Oncology Biology Physics | Q2296252 |
| P1476 | title | Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide | |
| P478 | volume | 77 |
| Q33797741 | Comprehensive analysis of MGMT promoter methylation: correlation with MGMT expression and clinical response in GBM |
| Q55052526 | Concordant association validates MGMT methylation and protein expression as favorable prognostic factors in glioma patients on alkylating chemotherapy (Temozolomide). |
| Q48365746 | Decision making and management of gliomas: practical considerations |
| Q39339970 | Effect of Bevacizumab Plus Temozolomide-Radiotherapy for Newly Diagnosed Glioblastoma with Different MGMT Methylation Status: A Meta-Analysis of Clinical Trials |
| Q33393291 | Immature and absolute platelet count changes and thrombocytopenia in malignant glioma |
| Q35850389 | MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR |
| Q37649471 | MGMT promoter methylation in malignant gliomas: ready for personalized medicine? |
| Q35803479 | MGMT promoter methylation in serum and cerebrospinal fluid as a tumor-specific biomarker of glioma |
| Q38044236 | MGMT testing for glioma in clinical laboratories: discordance with methylation analyses prevents the implementation of routine immunohistochemistry |
| Q38194054 | Microenvironmental clues for glioma immunotherapy |
| Q37221207 | Personalized treatment strategies in glioblastoma: MGMT promoter methylation status |
| Q34062033 | Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma |
| Q37641600 | Predicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide |
| Q35420548 | Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: one step forward, and one step back? |
| Q28731328 | Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma |
| Q34478948 | Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review). |
| Q31118089 | Restoration of sensitivity in chemo-resistant glioma cells by cold atmospheric plasma |
| Q36542980 | Role of Biomarkers in the Clinical Management of Glioblastomas: What are the Barriers and How Can We Overcome Them? |
| Q38393472 | Severe cholestatic hepatitis due to temozolomide: an adverse drug effect to keep in mind. Case report and review of literature. |
| Q26824754 | Severe sustained cholestatic hepatitis following temozolomide in a patient with glioblastoma multiforme: case study and review of data from the FDA adverse event reporting system |
| Q48476809 | Strength of skeletal muscle and self-reported physical performance in Austrian glioblastoma-patients. |
| Q92495586 | Survival analysis of patients with glioblastoma treated by long-term administration of temozolomide |
| Q99582351 | The Effects of O6-methyl Guanine DNA-methyl Transferase Promotor Methylation and CpG1, CpG2, CpG3 and CpG4 Methylation on Treatment Response and their Prognostic Significance in Patients with Glioblastoma |
| Q38579564 | The efficacy and safety of various dose-dense regimens of temozolomide for recurrent high-grade glioma: a systematic review with meta-analysis |
| Q37815545 | The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations |
| Q39266259 | The predictive but not prognostic value of MGMT promoter methylation status in elderly glioblastoma patients: a meta-analysis |
| Q47110239 | Tumor response of temozolomide in combination with morphine in a xenograft model of human glioblastoma |
| Q55460052 | [Treatment of the glioma microenvironment]. |
Search more.